Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transepithelial CXL for Keratoconus and Corneal Ectasia
NCT01464268Phase 3Active, not recruiting
- Sponsor
- Cornea and Laser Eye Institute
- Start
- Nov 2011
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of riboflavin in keratoconus, corneal ectasia, sponsored by Cornea and Laser Eye Institute. Started Nov 2011; status: active, not recruiting.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT01464268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01464268.